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Summary 
Mast ceils  are the main effector cells  of immediate hypersensitivity and anaphylaxis. Their role 
in  the  development  of allergen-induced  airway hyperresponsiveness  (AHR)  is  controversial 
and based on indirect evidence. To address these issues,  mast cell-deficient mice  (W/W  v) and 
their congenic littermates were sensitized to ovalbumin (OVA) by intraperitoneal injection and 
subsequently challenged with OVA via the airways. Comparison of OVA-specific immunoglo- 
bulin E  (IgE) levels in the serum and numbers of eosinophils in bronchoalveolar lavage fluid or 
lung digests showed no differences between the two groups of mice. Further, measurements of 
airway  resistance  and  dynamic  compliance  at  baseline  and  after  inhalation  of methacholine 
were similar.  These data indicate that mast cells or IgE-mast cell activation is not required for 
the development of eosinophilic inflammation and AHR in mice sensitized to allergen via the 
intraperitoneal route and challenged via the airways. 
M 
ast cells play a central role in immediate allergic reac- 
tions  (1)  and in the  early phase  of the asthmatic re- 
sponse, but their role in the late phase response or sustained 
airway hyperresponsiveness  is  not clearly defined.  Arming 
and activation of mast ceils is through the binding oflgE to 
high affinity IgE receptors  (FcelLI)  on the  cell surface  (2, 
3).  After antigen cross-linking,  the  cells  discharge a group 
of mediators  including  histamine  and  leukotrienes  (4,  5), 
which trigger immediate responses. The fact that mast cells 
may also synthesize and secrete several cytokines on activa- 
tion,  including IL-4 and  TNF-oL, indicates  their  potential 
role in the sustained airway abnormalities. It is largely based 
on circumstantial evidence that mast cells are implicated in 
asthma pathogenesis. Because many other cell types express 
high or low affinity receptors for IgE and can release bio- 
logically active  mediators  on  activation  (6),  a  number  of 
other cell types may be important in the IgE-dependent re- 
sponses in the airways. 
Mast cell-deficient mice can be used to directly assess the 
role  of mast  cells  in  allergen-driven  airway  hyperrespon- 
siveness (AHP,)  (7).  However, there have been limited in- 
vestigations of these mice in terms of airway inflammation 
and the development of AHR. In the present study, we as- 
sessed the physiological response of the airways after sensiti- 
zation  and  challenge  to  OVA in  W/W v,  genetically  mast 
cell-deficient mice to investigate more directly the role of 
the mast ceil. 
Materials and Methods 
Animals.  Female  mast  cell-deficient  ([VgB/Rej-kitW/+  × 
C57BL6J-kit  w - v/+]F1  -  [W/Wv]mice)  (W/W') and congenic 
WBB6F1 normal mice (+/+) from 8 to 12 wk of age were ob- 
tained from Jackson Labs. (Bar Harbor, ME).  The animals were 
maintained  on an OVA-free diet.  Experiments were conducted 
under a protocol approved by the Institutional  Animal Care and 
Use  Committee  of the  National Jewish Medical  and Research 
Center. 
Sensitization and Ainvay Challenge.  Groups  of mice (6-10 mice/ 
group/experiment)  receiving the following treatment were stud- 
ied: (a) airway challenge  to nebulized OVA alone (N); (b) sensiti- 
zation to OVA with alum plus aerosolized  airway challenge  with 
nebulized OVA (ipN).  Mice were immunized by intraperitoneal 
injection of 20 ~g of OVA (Grade  V; Sigma  Chemical Co., St. 
Louis,  MO)  emulsified  in 2.25  mg alum (Alumlmuject; Pierce, 
Rockford, IL) in a total volume of 100 t,1 on days 1 and 14. Mice 
were challenged via the airways with OVA (1% in saline) for 20 
rain on days 28, 29, and 30 by ultrasonic  nebulization,  and as- 
sessed 48 h after the last OVA exposure for AHR. 
Determination of Airway Responsiveness.  Airway  responsiveness 
was assessed as a change in airway function after  challenge  with 
aerosolized  methacholine  (MCh)  via the airways.  Anesthetized, 
tracheostomized  mice  were  mechanically  ventilated  and  lung 
function was assessed using methods similar to those described  by 
Martin et al.  (8). A four-way connector was attached to the tra- 
cheostomy tube, with two ports connected to the inspiratory and 
expiratory sides of a ventilator  (model 683;  Harvard Apparatus, 
South Natick, MA). Ventilation was achieved at 160 breaths/min 
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pressure of 2-4 cm H20. 
The Plexiglas chamber containing the mouse was  continuous 
with a  1.0-liter glass  bottle  filled with  copper  gauze  to  stabilize 
the volume signal for thermal drift. Transpulmonary pressure was 
detected by a pressure transducer with one side connected to the 
fourth port  of the  four-way  connector and  the  other side  con- 
nected to a second port on the plethysmograph.  Changes in lung 
volume were measured by detecting pressure changes in the ple- 
thysmographic  chamber  through  a  port  in  the  connecting  tube 
with a pressure transducer and then referenced to a second copper 
gauze-filled  1.0-liter  glass  bottle.  Flow was  measured  by digital 
differentiation of the volume signal. Lung resistance (ILL) and dy- 
namic  compliance  (Cdyn)  were  continuously  computed  (Lab- 
view,  National  Instruments,  TX)  by  fitting  flow,  volume,  and 
pressure to an equation of motion. 
Aerosolized agents were administered for 10 s with a tidal vol- 
ume of 0.5 ml (9).  From 20 s up to 3 min after each aerosol chal- 
lenge,  the  data  of ILL  and  Cdyn  were  continuously  collected. 
Maximum values of ILL and minimum values of Cdyn were taken 
to express changes in murine airway function. 
Bronchoalveolar Lavage and Lung Cell Isolation.  Immediately after 
assessment  of AHtL, lungs were lavaged via the tracheal tube with 
HBSS (1 ×  1 nil 37°C). The volume of collected bronchoalveolar 
lavage (BAL) fluid was measured in each sample and numbers of 
leukocytes were counted  (Coulter Counter;  Coulter Corporation, 
Hialeah,  FL).  Cells in  lung  tissue  were  isolated  and  counted  as 
previously described (10). 
Histologic and Immunohistochemistry Studies.  After  perfusion  via 
the right ventricle, lungs were inflated through the trachea with 2 
ml air and then  fixed in  10% formalin by immersion.  Blocks of 
the left lung tissue were cut from around the main bronchus and 
embedded in paraffin blocks, 5-btm tissue sections were affixed to 
microscope slides and deparaffinized. The slides were then stained 
with Astra Blue/Vital New Red  and  mast  cells and  eosinophils 
were examined under light microscopy (11). 
Cells containing eosinophilic major basic protein  (MBP) were 
identified  by  immunohistochemical  staining  as  previously  de- 
scribed  using  a  rabbit  anti-mouse  MBP  (provided  by  Dr.  G. 
Gleich and Dr. J. Lee, Mayo Clinic, Rochester, MN and Scotts- 
dale, AZ, respectively) (12).  Numbers  of eosinophils in the sub- 
mucosal  tissue  around  central  airways  were  analyzed  using  the 
IPLab2  software  (Signal Analytics,  Vienna,  VA)  for the  Macin- 
tosh counting four different sections per animal (12). 
Measurement of  Anti-OVA Antibody.  Serum  levels of anti-OVA 
IgG1 and IgE were measured by ELISA as previously described (10). 
Statistical Analysis.  All results  are  expressed  as  the  mean and 
SEM. Analysis of variance was used to determine the levels of dif- 
ference between  all  groups.  Pairs  of groups  were  compared  by 
unpaired  two-tailed Student's  t test. ANOVA was used to com- 
pare  percent  changes  of ILL and  Cdyn between  different strains 
with the same treatment. The p values for significance were set to 
0.05. 
Results 
Antibody  Responses  to  OVA  Sensitization  and  Challenge. 
As  shown  in  Fig.  1,  serum  levels  of anti-OVA  IgE  and 
IgG1  were comparable  in the mast  cell-deficient mice and 
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Figure 1.  OVA-specific  antibody in the serum. Serum titers for OVA- 
specific antibodies in +/+  and  W/V~ mice were determined  after sensi- 
tization  and  challenge  (n  =  7) compared  with mice receiving challenge 
alone (n =  6). The results for each of the groups are expressed as means -4- 
SEM.  *Significant differences  (P <0.05)  between the groups  (N versus 
IpN). EU, ELISA units; N, challenge (nebulization alone); ipN, sensitiza- 
tion and challenged. 
Figure 2.  (a) Cellular composition  of BAL fluid. Mice were sensitized 
and challenged as described in Materials and Methods.  BAL fluid was ob- 
tained from the same groups described in the legend to Fig. 1. The results 
for each group are expressed as means  +  SEM.  *Significant differences 
(P <0.05)  between the groups  (N versus lpN). (b) Cellular composition 
of isolated lung cells. Lung cells were prepared  from animals sensitized 
and challenged as described in the legend to Fig. 1. The results for each 
group  are expressed as means  +  SEM (n =  4/group). *Significant differ- 
ences (P <0.05) between the groups (N versus IpN). 
450  Airway Hyperresponsiveness in Mast Cell-deficient Mice Figure 3.  Immunohistochemistry  of peribronchial tissue after sensitization and challenge with OVA. Localization of eosinophils and mast cells are 
shown. +/+ mice are shown in a and c and W/V¢  v mice in b and d. In c and d, cells were stained with Astra Blue/Vital New Red. For a and b, staining 
was with a rabbit anti-mouse MBP antibody and fluorescein-labeled goat anti-rabbit IgG. Original magnification of  500. 
the  congenic  littermates  after  sensitization  and  challenge 
with OVA. Challenge alone on three occasions was insuffi- 
cient to trigger antibody responses in either group of mice. 
Eosinophilic Accumulation  in the BAL and Lung.  As  shown 
in  Fig.  2  a,  sensitization  and  challenge  with  OVA  had  a 
marked effect on the numbers and composition of the cells 
recovered.  In both groups of mice,  macrophages were the 
predominant  cell  type  in  the  mice  receiving  three  chal- 
lenges with  OVA alone  (similar to  control mice;  data not 
shown).  However,  after  both  sensitization  and  challenge, 
cell  numbers  increased  and  the  predominant  cells  in  the 
BAL were eosinophils, comprising roughly 60% of the cells 
in both the mast cell-deficient and congenic httermates. 
When  lung  digests  were  examined,  sensitization  and 
challenge  also resulted  in  a  marked  increase  in  eosinophil 
numbers  (Fig.  2  b),  although total  cell numbers were little 
changed when  compared with  challenge  alone.  As  in  the 
BAL, there were no differences in the numbers  of eosino- 
phils in the lung digests between  mice that were mast cell 
deficient or sufficient. 
Localization  of Eosinophils  and Mast  Cells  in  Lung  Tissue. 
After  staining  with  anti-MBP  antibody,  sensitization  and 
challenge significantly increased the numbers ofeosinophils 
per area in the peribronchial tissue of both groups of mice 
(Fig.  3,  a  and b)  to  187  +  23/ram  2 in  +/+  mice,  168  -+ 
18/ram  2 in  W/W ~ mice  (n  =  4).  In  animals  challenged 
alone very few eosinophils were detected in these sites  (13  - 
4/ram2). Staining with Astra Blue/Vital New Red revealed 
the  accumulation of mast cells  in the submucosal tissue  of 
the bronchi in sensitized  and challenged  +/+  mice (Fig. 
3 c). None could be identified in any of the sections exam- 
ined from W~ Ill/v mice (Fig. 3  d). 
Airway Responsiveness.  We  examined baseline  lung func- 
tion and assessed the airway response to inhaled methacho- 
line. Baseline (before MCh challenge) measures of  lung func- 
tion as assessed  with I~L and Cdyn are presented in Table 1. 
The  values  in  all  four  groups  were  comparable.  The  re- 
sponse to aerosohzed methacholine in mice that were chal- 
lenged with  antigen  alone  revealed small,  dose-dependent 
changes in Ikz and a 20-30% dose-dependent fall in Cdyn 
(Fig. 4).  After sensitization and challenge,  resistance  values 
increased by almost fivefold and dynamic  compliance was 
reduced by 60--70% with  comparable  doses  of methacho- 
hne.  The  responses in the mast cell-deficient  mice,  if any- 
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Mice  Group  tkL  Cdyn 
cmH20"ml-:'sec  ml'cm 1-12  0-I 
+/+  N  0.45  +  0.057  0.039 +  0.0012 
W/V~  N  0.42 +  0.070  0.039 +  0.0013 
+/+  ipNeb  0.40 +  0.062  0.036 _  0.0020 
W/V~  ipNeb  0.44 -+ 0.063  0.035 +  0.0018 
Lung resistance and dynamic compliance values in sensitized and chal- 
lenged mice. RL and Cdyn values were obtained in the different groups 
of animals after sensitization and challenge but before exposure to MCh. 
The results for each group are expressed as means +  SEM (n =  8). 
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thing,  exceeded  the  response  in  the  congenic littermates, 
with  a shift to the left in the  methacholine  dose-response 
curve for both tkL and Cdyn. 
Discussion 
Mast cells and their released products are widely believed 
to contribute to the development of allergic respiratory dis- 
orders.  IgE-dependent activation  of mast  cells  can induce 
these cells to release a panel of preformed or newly synthe- 
sized mediators including histamine,  tryptase, prostaglandins, 
]eukotrienes, and platelet activating factor, which can result 
in acute phase  allergic  reactions in the lung including air- 
way  obstruction,  airway  microvascular  leakage,  and  mu- 
cosal  edema,  as  well  as  mucus  gland  hypersecretion  (13- 
15). Although a role for mast cells  has been defined in the 
acute phase of allergic reactions, much less is known about 
their  role  in  chronic  allergic  lung inflammatory responses 
and  their  contribution  to lung dysfunction in this  setting. 
After allergen sensitization and challenge in the mouse, the 
changes in airway function that have generally been moni- 
tored  include  the  response  to MCh  (8)  or electrical  field 
stimulation of tracheal smooth muscle preparations (16) and 
likely reflect a more chronic, eosinophil-dependent response 
(12).  The current study extends previous investigations by 
assessing airway responsiveness in vivo and factors, such as 
cells and antibodies,  which may contribute to the develop- 
ment of airway responsiveness. 
Sensitization and challenge of the mast cell-deficient mice 
resulted  in  IgE  and  IgGl-specific  antibody responses,  in- 
creased eosinophils in the BAL and lung digests,  and peri- 
bronchial infiltration  of eosinophils.  In all  of these aspects, 
they were indistinguishable from their congenic littermates. 
The only difference was that mast cells were identified his- 
tologically in the submucosa of +/+  mice and not in the 
W~ l/I/v animals.  These  findings  suggest  that  the  develop- 
ment of an allergic inflammatory reaction is not dependent 
on the  presence  of functional  mast cells.  These  results  are 
similar to what has been suggested in other systems. For ex- 
ample,  Nogami  and  coworkers  (17)  showed no  evidence 
for the involvement of mast cells in the pulmonary eosino- 
Figure 4.  Lung resistance (A), and pulmonary dynamic compliance (B) 
in sensitized and challenged mice. KL and Cdyn values were obtained in 
response to increasing concentrations of methacholine as described in 
Materials and Methods. The results for each group are expressed as means 
+  SEM (n =  8). *Significant differences (P <0.05) between the groups. 
+Significant differences (P <0.05) between W~ W  ~  and + / + mice. 
philic response to challenge with an extract from the para- 
site Ascaris suum.  Further, Brusselle et al.  (18) demonstrated 
no effect of mast cells on eosinophil influx in BAL fluid af- 
ter  repeated  challenge  with  OVA  in  sensitized  mice.  In 
contrast,  Kung et al.  (19)  reported that OVA challenge of 
sensitized mast cell---deficient mice produced fewer eosino- 
phils  in the  BAL fluid and lungs compared with  similarly 
sensitized  and  challenged  congenic littermates.  However, 
in this study both the  sensitization  and challenge protocol 
were attenuated and the number of eosinophils was signifi- 
cantly lower than we and others  (18)  generally observe af- 
ter sensitization and challenge as described in this study. In 
their protocol, mice were challenged with antigen on only 
1 d; in our studies we have found that  1 or 2  d  of antigen 
challenge  were  not  sufficient  to  develop  airway hyperre- 
sponsiveness  (our unpublished  data).  In our protocol,  air- 
way inflammation  and  eosinophil  accumulation may have 
been  sufficiently  strong  so  that  a  role  for  the  mast  cells 
could not be demonstrated. 
The presence  of a  comparable  peribronchial  eosinophil 
response in the  W~ H/v and  +/+  mice was associated with 
a similar response to MCh in this study.  Monitoring both 
resistance  and  dynamic  compliance,  aerosolized MCh  re- 
suited in a dose-dependent  increase in RL as well as a 60- 
70% decrease in compliance. These changes were only ob- 
served in sensitized and challenged animals. At virtually all 
concentrations  of MCh,  the  findings  in  the  W~ ~  mice 
exceeded  those in the  +/+  mice.  At present,  there  is no 
apparent  explanation  for these  differences.  One possibility 
is that in the airways of mast cell-sufficient animals, heparin 
is released after activation (20), and may limit the response 
to the cationic protein mediators released by these same or 
other cells.  In this regard, it has been previously shown that 
heparin  sulfate  and other polyanionic molecules block the 
452  Airway Hyperresponsiveness in Mast Cell-deficient  Mice increase in airway responsiveness caused by highly charged 
cationic proteins  (21, 22). 
If sensitization and repeated challenge with antigen trig- 
gers  both  eosinophilic  inflammation  and  AHR,  does  this 
eliminate a role for mast cells in the  development  of these 
changes?  It is possible that the  same physiologic  response, 
AHR  to MCh  challenge, may be mediated by distinct cel- 
lular mechanisms  in different  strains  of mice  (23).  For ex- 
ample, in BALB/c mice AHR  could be induced in an IgE 
and mast cell-dependent  fashion. In strains genetically defi- 
cient in important mast cell mediators  (e.g.,  mast cell pro- 
tease 7  deficiency in  C57BL/6  mice)  AHR  may be more 
dependent  on  other  cell  types,  such  as  eosinophils.  Mast 
cell deficient mice of the same background  as studied here 
do demonstrate reduced severity of anaphylaxis induced by 
anti-IgE treatment as well as reduced airway responsiveness 
to  MCh  shortly  after  systemic  administration  of anti-IgE 
(25, 26). 
After limited bronchoprovocation  mast cells may play a 
role in the  liberation  of cytokines such  as IL-4,  IL-5,  and 
TNF-ot  (15); because of preformed stores, mast cells could 
provide the initial source of TNF-¢i in  IgE-dependent  re- 
actions  (27).  However,  we have shown in nude mice that 
were  passively  sensitized  with  IgE,  that  despite  adequate 
mast cell degranulation,  insufficient  cytokines are liberated 
to trigger an eosinophilic  response (28). A  similar inconsis- 
tency centers  around  the  role of IgE in triggering  allergic 
inflammation  and  AHR.  Sensitization  exclusively  via  the 
airways, which results in limited eosinophilic infiltration of 
the peribronchial regions, results in AHR that appears to be 
IgE dependent  (29).  On the other hand,  after sensitization 
and challenge as performed in this study, AHR  may be IgE 
independent  but  eosinophil  dependent  (our  unpublished 
data).  Similar results have recently been reported by Kors- 
gren et al.  (30) demonstrating normal development of eosin- 
ophilic airway inflammation in B  cell--deficient mice. How- 
ever,  we  can  not  discount  that  in  the  mast  cell-deficient 
mice, the presence of a normal IgE response serves to trig- 
ger other cells expressing either high aflqnity IgE receptors, 
e.g.,  basophils,  macrophages,  or other cells expressing low 
aflfinity receptors  (6)  to release important proinflammatory 
mediators. 
In summary, in this study of mast cell-deficient mice we 
have  shown  that  after  sensitization  and  airway  challenge 
they  are  capable  of developing  an  allergic  antibody  re- 
sponse and changes in airway resistance and dynamic com- 
pliance  that  are  similar  to  their  congenic  littermates.  Al- 
though this does not exclude contributions  of mast cells in 
other aspects of chronic  allergic inflammatory responses, it 
indicates that mast cells do not have an essential role in de- 
velopment of eosinophilic airway inflammation and airway 
hyperresponsiveness  to  MCh  in  mice  sensitized  and  chal- 
lenged as described in this report. 
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